Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma (AxitinibACC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02859012

Recruitment Status : Completed

First Posted : August 8, 2016

Last Update Posted : March 29, 2022

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Bhumsuk Keam, Seoul National University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	December 2017
Actual Study Completion Date :	August 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kang EJ, Ahn MJ, Ock CY, Lee KW, Kwon JH, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Nam BH, Kim SB, Keam B. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2021 Oct 1;27(19):5272-5279. doi: 10.1158/1078-0432.CCR-21-1061.

To Top